Want to see JP:4564 full AI Analyst Report?

OncoTherapy Science (4564) Price & Analysis

2 Followers

4564 Stock Chart & Stats

¥21.00

-¥1.00(-4.17%)

At close: Jan 08 4:00 PM EST

¥21.00

-¥1.00(-4.17%)

Day’s Range― - ―

52-Week Range¥18.00 - ¥34.00

Previous CloseN/A

Volume4.29M

Average Volume (3M)157.78M

Market Cap

¥7.76B

Enterprise Value¥4.85B

Total Cash (Recent Filing)¥1.23B

Total Debt (Recent Filing)¥37.14M

Price to Earnings (P/E)―

Beta1.07

Next Earnings

Jan 29, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.03

Shares Outstanding408,243,700

10 Day Avg. Volume207,340,870

30 Day Avg. Volume157,776,776

Financial Highlights & Ratios

PEG Ratio0.68

Price to Book (P/B)3.22

Price to Sales (P/S)8.53

P/FCF Ratio-7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero debt and a larger equity base provide financial flexibility for an oncology company funding research and development. The stronger capital cushion can reduce immediate refinancing pressure and support continued operations, although it does not eliminate the need to control losses and cash use.

Gross Margin RecoveryThe return to slightly positive gross margin indicates that the economics of reported revenue improved compared with prior periods. If maintained, this could strengthen the foundation for future partnering or commercialization, though operating performance remains constrained by substantial ongoing costs.

Positive Reported EPS GrowthReported positive EPS growth suggests per-share performance improved versus the comparison period, which may indicate some progress in underlying results. Its significance is limited because the company remains loss-making, but continued improvement could support a gradual recovery in earnings quality.

Bears Say

Declining And Volatile RevenueVolatile and declining revenue makes the company’s commercial trajectory difficult to establish and reduces visibility into the durability of its oncology business model. Without sustained top-line expansion, fixed research and operating costs remain harder to absorb over the next several quarters.

Persistent Deep LossesLosses that remain roughly comparable to revenue show that the current business is far from operating profitability. Persistent negative margins can consume the balance-sheet cushion over time and may restrict the company’s ability to fund oncology development internally without additional capital.

Ongoing Cash BurnNegative operating and free cash flow demonstrate that reported losses are translating into substantial cash outflows rather than being mainly non-cash accounting effects. Continued burn increases reliance on external funding and creates a durable risk to development continuity and financial flexibility.

4564 FAQ

What was OncoTherapy Science, Inc.’s price range in the past 12 months?

OncoTherapy Science, Inc. lowest stock price was ¥18.00 and its highest was ¥34.00 in the past 12 months.

What is OncoTherapy Science, Inc.’s market cap?

OncoTherapy Science, Inc.’s market cap is ¥7.76B.

When is OncoTherapy Science, Inc.’s upcoming earnings report date?

OncoTherapy Science, Inc.’s upcoming earnings report date is Jan 29, 2027 which is in 107 days.

How were OncoTherapy Science, Inc.’s earnings last quarter?

OncoTherapy Science, Inc. released its earnings results on Aug 07, 2026. The company reported -¥0.72 earnings per share for the quarter.

Is OncoTherapy Science, Inc. overvalued?

According to Wall Street analysts OncoTherapy Science, Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does OncoTherapy Science, Inc. pay dividends?

OncoTherapy Science, Inc. does not currently pay dividends.

What is OncoTherapy Science, Inc.’s EPS estimate?

OncoTherapy Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OncoTherapy Science, Inc. have?

OncoTherapy Science, Inc. has 408,243,700 shares outstanding.

What happened to OncoTherapy Science, Inc.’s price movement after its last earnings report?

OncoTherapy Science, Inc. reported an EPS of -¥0.72 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of OncoTherapy Science, Inc.?

Currently, no hedge funds are holding shares in JP:4564

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

OncoTherapy Science, Inc.

OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.